Drug
apricitabine
apricitabine is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
2
40%
Ph phase_3
1
20%
Ph phase_2
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Withdrawn1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Trials by Status
withdrawn120%
completed360%
terminated120%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_2
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
NCT00612898
completedphase_2
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
NCT00367952
completedphase_1
A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
NCT00334659
withdrawnphase_3
A Long Term Safety Study of Apricitabine in HIV-infected Patients
NCT00686270
completedphase_1
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
NCT00352066
Clinical Trials (5)
Showing 5 of 5 trials
NCT00612898Phase 2
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
NCT00367952Phase 2
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
NCT00334659Phase 1
A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
NCT00686270Phase 3
A Long Term Safety Study of Apricitabine in HIV-infected Patients
NCT00352066Phase 1
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5